IP Group plc - Share buyback programme update

IP Group plc (LSE: IPO) ("IP Group" or "the Group" or "the Company"), which invests in breakthrough science and innovation companies with the potential to create a better future for all, is pleased to provide the following update.

In line with its previously announced intention, the Group is now allocating all of the proceeds it has received to date from the secondary sale announced on 09 December 2024 together with 50% of the Group's other realisations received in 2025, being £20m in aggregate, towards its buyback programme (the "Buyback Programme").  The Buyback Programme will therefore today be extended by £20m to a total of £75m (the "Buyback Extension").

The Buyback Extension will run until 31 December 2025 unless completed or terminated earlier, or unless the Company and Deutsche Numis agree otherwise (in which event an announcement would be made).

Since commencing the Buyback Programme, the Group has purchased 122,904,597 shares at an average price of 44.8 pence per share for an aggregate consideration of £55m. All shares acquired under the Buyback Programme have been, or will shortly be, cancelled. Following such cancellation, the Company's issued share capital consists of 918,491,679 Ordinary Shares with voting rights and there are no Ordinary Shares held in treasury.

Details of the Buyback Extension

For the Buyback Extension, IP Group has entered into a non-discretionary agreement with Deutsche Numis to continue to manage the Buyback Programme on its behalf. Deutsche Numis will make its trading decisions in relation to the Ordinary Shares independently of the Group.

Any Ordinary Shares purchased under the Buyback Extension will be cancelled.

The Buyback Extension is in accordance with IP Group's general authority to purchase a maximum of 141,415,378 Ordinary Shares granted by its shareholders at the Annual General Meeting held on 12 June 2025. The Buyback Programme will continue to be effected within the parameters of the Market Abuse Regulation 596/2014/EU and the Commission Delegated Regulation 2016/1052/EU (as incorporated into UK domestic law by the European Union (Withdrawal) Act 2018), including where relevant pursuant to the Market Abuse (Amendment) (EU Exit) Regulations 2019), and in accordance with Chapter 9 of the Financial Conduct Authority's Listing Rules. IP Group confirms that it is not in a closed period and currently has no other unpublished price sensitive information.

Save to the extent they are varied by this announcement, all other parameters outlined in the Company's announcement on 18 December 2023 will continue to apply.

IP Group will continue to make further regulatory announcements to shareholders in respect of purchases of Ordinary Shares by the Group as they occur.

For more information, please contact:

Notes for editors

About IP Group

IP Group accelerates the impact of science for a better future. As the most active UK based, early stage science investor, we develop and support some of the world's most exciting businesses in deeptech, life sciences and cleantech (led by Kiko Ventures). Through Parkwalk, the UK's largest growth EIS fund manager, we also back world-changing innovation emerging in leading universities and research institutions. Our specialist investment team combines sector expertise with an international approach. Together we have a strong track record of success, having backed high-profile companies including Oxford Nanopore Technologies plc, Featurespace, First Light Fusion, Hysata, and Oxa. IP Group is listed on the Main Market of the London Stock Exchange under the code IPO. For more information, please visit our website at www.ipgroupplc.com.

 ENDS